Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.63 USD
Change Today +0.05 / 1.09%
Volume 233.4K
BTX On Other Exchanges
BTX is not on other exchanges.
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $5.95
52 Week Low
05/27/14 - $2.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOTIME INC (BTX)

biotime inc (BTX) Related Businessweek News

No Related Businessweek News Found

biotime inc (BTX) Details

BioTime, Inc., a biotechnology company, engages in the research and product development in the field of regenerative medicine. The company focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including PureStem human embryonic progenitor cell lines; associated ESpan culture media; human embryonic stem cell lines; HyStem hydrogel products; and Hextend, a blood plasma volume expander for hypovolemia in surgery, emergency trauma, and other applications. The company’s clinical programs include OpRegen and OpRegen-Plus, which are in Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1 that is in Phase I/IIa trial for spinal cord injuries; Renevia, which is in pivotal trial for HIV-related lipoatrophy; and AST-VAC2 that is in pre-clinical stage for non-small cell lung cancer. It is also developing Premvia, a hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and PanC-Dx, a diagnostic product used to detect breast, bladder, and lung cancers, as well as mobile health software products. In addition, the company markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; VarElect, an application for prioritizing gene variants; and MalaCards, a database of human diseases, as well as analysis tools. Further, it develops cell based therapeutic products for diseases, such as neurological, cancer, age related macular degeneration, orthopedic, and age-related cardiovascular diseases. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

117 Employees
Last Reported Date: 03/11/15
Founded in 1990

biotime inc (BTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $884.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $537.6K
Chief Operating Officer
Total Annual Compensation: $5.2K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $76.2K
Compensation as of Fiscal Year 2014.

biotime inc (BTX) Key Developments

BioTime, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioTime, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total consolidated revenues of $1,264,454 against $1,066,635 million in the first quarter 2014. Net loss attributable to the company was $10,167,368 or $0.13 per basic and diluted share against $8,099,014 or $0.14 per basic and diluted share a year ago. Loss before income tax benefits was $13,766,937 against $11,077,057 a year ago.

BioTime, Inc. and OncoCyte Corporation Announces Initial Data from Ongoing Clinical Study of Collagen Type X as A Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers

BioTime, Inc. and OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The controlled study, initiated at Scottsdale Medical Imaging Laboratories in Scottsdale, AZ, is ongoing and has nearly completed enrollment of over 600 patients. The goal of this study is to assess the performance of PanC-Dx™ in discriminating patients with malignant breast lesions from those with negative findings or benign findings. Study investigators are collecting blood samples from patients undergoing screening or diagnostic mammography. Patient blood samples are being assessed for levels of OncoCyte’s PanC-Dx™ markers, including the concentration of the protein COL10A1, using proprietary assays and the results are compared to radiological and pathology findings. Expression of the gene COL10A1 at an mRNA level has been shown in past studies to be significantly elevated in multiple and diverse malignant tumor types including cancers of the breast, stomach, colon, lung, bladder, pancreas, and ovaries. In addition, the protein was shown to be specifically localized within tumor vasculature. Early data showed that PanC-Dx™ identified a mean concentration of COL10A1 protein in sera of breast cancer patients (n=33) that was 35% higher than the mean COL10A1 value in sera of normal individuals (n=32). No significant differences were noted when comparing breast cancer patients to patients with confirmed benign disease suggesting that additional biomarkers may be necessary to discriminate these two populations. Based on this data, PanC-Dx™ offered improved performance as compared to the commercially available enzyme-linked immunosorbent assay (ELISA) manufactured with polyclonal antibodies that study investigators previously used in analyzing over 400 serum samples from healthy volunteers and cancer patients. Evaluation of the performance of PanC-Dx™ demonstrated 86% area-under-the-curve (AUC) of the Receiver Operating Characteristic (ROC) curve, which determines the level of specificity and sensitivity of the product. The polyclonal ELISA demonstrated 74% AUC of the ROC curve.

BioTime, Inc. and Oncocyte Corporation Announce Positive Clinical Results of Panc-Dx, Oncocyte’s Class of Proprietary, Non-Invasive Cancer Diagnostic Tests, in Detecting the Most Common Type of Bladder Cancer, Urothelial Carcinoma

BioTime, Inc. and its subsidiary OncoCyte Corporation announced positive clinical results of PanC-Dx, OncoCyte’s class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma. The first clinical study was conducted by OncoCyte in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine led by Matthew T. Olson, M.D., Assistant Professor and Associate Director of the Division of Cytopathology in the Department of Pathology at Johns Hopkins University School of Medicine and principal investigator of the trial, and Dorothy Rosenthal, M.D., Professor of Pathology, Oncology and Gynecology/Obstetrics at Johns Hopkins University School of Medicine and collaborator on the study. Clinical investigation involved collection of 90 urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. Patient urine samples were assessed microscopically for the presence of cancer cells using the current standard-of-care method of cytopathology; in parallel, study investigators analyzed the urine samples for gene expression. Study investigators then investigated the performance the 43-marker panel derived from the first clinical study using a set of 195 urine samples obtained from a second, large ongoing clinical study at multiple urology clinics in the United States. Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $4.63 USD +0.05

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $4.03 USD -0.01
Ocata Therapeutics Inc $6.73 USD +0.11
Organovo Holdings Inc $4.65 USD -0.03
ReNeuron Group PLC 5.50 GBp +0.375
ReproCELL Inc ¥669.00 JPY +4.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.6x
Price/Book 15.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at